Last edition
News about "Cohance Lifesciences"
Cohance Lifesciences Jaggaiahpet API Plant Clears US FDA Inspection with Zero Observations
Cohance Lifesciences has announced that its API manufacturing facility in Jaggaiahpet, Andhra Pradesh, has successfully cleared a US Food and Drug Administration current Good Manufacturing Practices (cGMP) audit with zero Form 483 observations.
Cohance Lifesciences | 15/09/2025 | By Darshana | 178
Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations
The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences' API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations.
Cohance Lifesciences | 12/09/2025 | By Dineshwori | 210
Cohance Lifesciences Invests INR 23 Cr on New cGMP Oligonucleotide Facility at Hyderabad
Cohance Lifesciences has announced an investment of INR 230 million and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India.
Cohance Lifesciences | 13/08/2025 | By Dineshwori | 199
Cohance Lifesciences to Invest USD 10 Million to Expand cGMP Bioconjugation Capabilities in US
Cohance Lifesciences will invest USD 10 million to expand cGMP bioconjugation capabilities at its US-based subsidiary NJ Bio, strengthening its integrated Antibody-Drug Conjugate manufacturing capacity for global innovators.
Cohance Lifesciences | 13/08/2025 | By Mrinmoy Dey | 162
Suven Pharmaceuticals Secures NCLT Approval for Merger with Cohance Lifesciences
Over 99.9994 percent of Suven’s equity shareholders and 99.967 percent of Cohance’s shareholders voted in favor of the Scheme of Amalgamation during meetings held on November 28, 2024.
Cohance Lifesciences | 31/03/2025 | By Aishwarya | 484
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy